Early BAFF receptor blockade mitigates murine Sjögren's syndrome: Concomitant targeting of CXCL13 and the BAFF receptor prevents salivary hypofunction
详细信息 查看全文
- 作者：Arjun Sharmaa ; 1 ; Jeremy Kiripolskya ; 1 ; 2 ; Ekaterina Klimatchevab ; Alan Howellb ; Farzad Fereidounic ; Richard Levensonc ; Thomas L. Rothsteind ; e ; f ; Jill M. Kramera ; d ; e ; g ; jkramer@buffalo.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：ANA ; anti-nuclear autoantibodies ; BAFF ; B-cell activating factor of the tumor necrosis factor family ; BAFFR ; BAFF receptor ; cLN ; cervical lymph node ; FLS ; focal lymphocytic sialadenitis ; M3R ; muscarinic 3 acetylcholine receptor ; RF ; rheumatoid factor ; SMG ; submandibular gland ; SS ; Sjö ; gren's syndrome ; TACI ; transmembrane activator and CAML interactor
- 刊名：Clinical Immunology
- 出版年：2016
- 出版时间：March 2016
- 年：2016
- 卷：164
- 期：Complete
- 页码：85-94
- 全文大小：1469 K
文摘
- •
Blockade of BAFF receptor (BAFFR) signaling prevents murine Sjögren's syndrome (SS)
- •
Treatment with anti-CXCL13 and BAFFR-Fc protects SS mice from salivary hypofunction.
- •
BAFFR-Fc alone and in combination with anti-CXCL13 may be effective in SS treatment.